A Phase 3 interventional study of DWP16001 Amg in T2DM (Type 2 Diabetes Mellitus), sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-25.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.
Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 8 in phase 3, and was the 5th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 20–79
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20–80
Yonsei University · Sites in Korea, Republic of
Ages 19+
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–80 · Healthy volunteers
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2021.
This study's enrollment of 63 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 140 across the 15 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 4 most frequent:
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD.: 6 open now, 10 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 20 studies in Diabetes Mellitus, Type 2 by Daewoong Pharmaceutical Co. LTD., this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 in phase 3, and was the 8th registered.
Daewoong Pharmaceutical Co. LTD.’s Diabetes Mellitus, Type 2 studies by the year they started, since 2015.
2 of the studies testing enavogliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07619833Phase 3Daewoong Pharmaceutical Co. LTD.To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus | 2027-11 |
| NCT06399835Seoul National University Bundang HospitalEnavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daewoong Pharmaceutical Co. LTD.’s 20 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is evaluate the long term safety and efficacy of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant or lactating women or those who do not consent to the use of appropriate methods during clinical trials Appropriate method of birth control for you or your partner: You must agree to one of the following
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DWP16001 Tablets
Drug: DWP16001 Amg
DWP16001 Amg, Tablets, Orally, Once daily
Changes from baseline in Adverse events (AEs) and adverse events of special interest (AESIs)* at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
\*Hypoglycemia, urinary tract infection, genital infection, pollakiuria, or polyuria
Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Changes from baseline* in HbA1c at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
\* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001301)
Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Changes from baseline* in FPG at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
\* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001301)
Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Proportion of subjects achieving HbA1c target of < 7% at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
\* Visit 2 (randomization) of the prior phase 3 study (Protocol No: DW_DWP16001301)
Time frame: at Weeks 6, 12, 18, 24, 38, and 52 after administration of the IP
Ran from Sep 2021 to primary completion in May 2022, 8 months.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin
Daewoong Pharmaceutical Co. LTD. →